Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03681704
Other study ID # 17401970500-a
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 8, 2018
Est. completion date December 31, 2021

Study information

Verified date May 2022
Source Shanghai University of Traditional Chinese Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Efficacy and Safety of treatment with Traditional Chinese Medicine HuangQi Decoctions in Patients with early stage of Diabetic Kidney Disease.


Description:

The study is a multi-center, randomized, double-blind, placebo-controlled trial. It is performed in Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, and Shanghai Baoshan District Hospital of Integrated Traditional Chinese Medicine and Western Medicine, China.


Recruitment information / eligibility

Status Completed
Enrollment 96
Est. completion date December 31, 2021
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Identify the diagnosis of type 2 diabetes; 2. It meets the medical history of diabetic kidney disease, according to the Mogensen diagnostic staging standard DKD III; 3. Age 18-75 years old, gender ðnicity are not limited; 4. glycated hemoglobin = 10%; 5. Blood pressure is controlled below 130/80mmHg Exclusion Criteria: 1. Combine other ACEI and ARB application indications other than hypertension; 2. Combine severe primary diseases related to heart, brain, liver and hematopoietic system; 3. Patients who have acute metabolic disorders such as diabetic ketoacidosis occur in the past month; 4. Patients who HBV serological indicators except HbsAb are positive and persistent liver function test transaminase abnormalities; 5. Patients with malignant tumors or history of malignant tumors, history of HIV infection, history of psychosis, acute central nervous system diseases, severe gastrointestinal diseases, and banned use of immunosuppressive agents; 6. Patients with acute renal failure, combined with urinary tract infection, menstrual period, intense exercise, cold and other stress states; 7. pregnant or lactating women; 8. Patients who accepted other clinical trial studies on going ; 9. Patients who combined with serious diseases and dysfunctions in other organs.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HuangQi Decoction
HuangQi Decoction 150ml twice a day for 24 weeks
HuangQi Decoction placebo
traditional Chinese medicine placebo mimic HuangQi Decoction 150ml twice a day for 24 weeks

Locations

Country Name City State
China Longhua Hospital, Shanghai University of Traditional Chinese Medicine Shanghai Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Shanghai University of Traditional Chinese Medicine Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary ACR the Urinary albumin/ creatinine ratios in stage ? diabetes kidney disease patients 24 weeks
See also
  Status Clinical Trial Phase
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Completed NCT04549324 - Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
Recruiting NCT03502031 - Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy Phase 4
Completed NCT03681249 - the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD Early Phase 1
Withdrawn NCT03504566 - Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2) Phase 4
Completed NCT03889236 - Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy. N/A
Completed NCT06326034 - Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients Phase 4
Recruiting NCT04931537 - Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Not yet recruiting NCT05373004 - Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease Phase 2/Phase 3
Recruiting NCT03622762 - Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT03445247 - Extracorporeal Low-intensity Shockwave in Diabetic Nephropathy N/A
Not yet recruiting NCT06068439 - Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy Phase 2/Phase 3
Recruiting NCT04143412 - Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination Phase 2
Not yet recruiting NCT06222476 - Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study. N/A
Completed NCT05487755 - Investigational and Comparative Study in the Management of Diabetic Nephropathy Phase 3
Active, not recruiting NCT04573920 - Atrasentan in Patients With Proteinuric Glomerular Diseases Phase 2
Recruiting NCT05888909 - Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
Not yet recruiting NCT04962399 - Relationship Between Serum N/OFQ and Type 2 Diabetic Nephropathy
Not yet recruiting NCT03591939 - T-regulatory Cells in Diabetic Type Two Nephropathy
Active, not recruiting NCT03859817 - Observational Study to Evaluate the Relationship Between Ketonemia and Renal Function in the Diabetic Patient